Please use this identifier to cite or link to this item: https://ir.swu.ac.th/jspui/handle/123456789/14294
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWeecharangsan W.
dc.contributor.authorLee R.J.
dc.date.accessioned2021-04-05T03:34:01Z-
dc.date.available2021-04-05T03:34:01Z-
dc.date.issued2012
dc.identifier.issn10717544
dc.identifier.other2-s2.0-84866256041
dc.identifier.urihttps://ir.swu.ac.th/jspui/handle/123456789/14294-
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84866256041&doi=10.3109%2f10717544.2012.714810&partnerID=40&md5=49c52723b72986b90604e875f73414ff
dc.description.abstractPrevious study has shown human serum albumin (HSA) coated liposomes can deliver bcl-2 antisense oligodeoxyribonucleotide (ODN) into KB carcinoma cells, and decrease bcl-2 mRNA and protein expression level. In the current study, cell growth inhibition and chemosensitization of KB cells were evaluated. Liposomes composed of dimethyldioctadecyl ammonium bromide/egg phosphatidylcholine/ α-tocopheryl polyethylene glycol 1000 succinate (58:40:2 molar ratio) complexed with bcl-2 antisense ODN and coated with HSA were examined for cell growth inhibition and sensitization to a commonly used chemotherapeutic drug, doxorubicin. HSA-coated liposomeODN complexes effectively inhibited cell growth in the range of ODN concentration of 0.457.2 M. Upon posttreatment with doxorubicin, the cytotoxicity was further significantly increased compared to the ODN complexes alone. The cytotoxicity was dependent on antisense ODN concentration, incubation time and doxorubicin concentration, and relatively independent on HSA concentration. This study suggests that HSA-coated liposomes are effective delivery vehicles for antisense ODN with potential therapeutic application and can be effectively combined with doxorubicin. © 2012 Informa Healthcare USA, Inc.
dc.subjectalpha tocopheryl polyethylene glycol 1000 succinate
dc.subjectantisense oligodeoxynucleotide
dc.subjectdimethyldioctadecyl ammonium bromide
dc.subjectdoxorubicin
dc.subjectegg phosphatidylcholine
dc.subjecthuman serum albumin
dc.subjectliposome
dc.subjectmessenger RNA
dc.subjectprotein bcl 2
dc.subjectunclassified drug
dc.subjectarticle
dc.subjectcarcinoma cell
dc.subjectcell growth
dc.subjectcell strain KB
dc.subjectchemosensitization
dc.subjectconcentration response
dc.subjectcontrolled study
dc.subjectcytotoxicity
dc.subjectdrug coating
dc.subjectdrug delivery system
dc.subjectgenetic transfection
dc.subjectgrowth inhibition
dc.subjecthuman
dc.subjecthuman cell
dc.subjectincubation time
dc.subjectmouth carcinoma
dc.subjectpriority journal
dc.subjectprotein expression
dc.subjectAntibiotics, Antineoplastic
dc.subjectCell Growth Processes
dc.subjectCell Line, Tumor
dc.subjectDose-Response Relationship, Drug
dc.subjectDoxorubicin
dc.subjectGene Expression Regulation, Neoplastic
dc.subjectHumans
dc.subjectKB Cells
dc.subjectLipids
dc.subjectLiposomes
dc.subjectMouth Neoplasms
dc.subjectOligodeoxyribonucleotides, Antisense
dc.subjectProto-Oncogene Proteins c-bcl-2
dc.subjectRNA, Messenger
dc.subjectSerum Albumin
dc.subjectTime Factors
dc.titleGrowth inhibition and chemosensitization of human carcinoma cells by human serum albumin-coated liposomal antisense oligodeoxyribonucleotide against bcl-2
dc.typeArticle
dc.rights.holderScopus
dc.identifier.bibliograpycitationDrug Delivery. Vol 19, No.6 (2012), p.292-297
dc.identifier.doi10.3109/10717544.2012.714810
Appears in Collections:Scopus 1983-2021

Files in This Item:
There are no files associated with this item.


Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.